Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Medicilon Assists CGeneTech's Oral Hypoglycemic DPP-4 Inhibitor, New Drug Application (NDA) AcceptedBy: Medicilon Shanghai Medicilon Inc. (Medicilon), as a partner of CGeneTech, provided Sitagliptin with comprehensive preclinical research services (https://www.medicilon.com/ Medicilon Preclinical Research Platform Help drug research and development faster, better and cost-efficient Efficiency comes from collaboration, and success comes from experience. Medicilon, as a one-stop comprehensive preclinical research and development service CRO for biopharmaceutical, has been continuously improving the scientific and technological innovation for 19 years, providing customized preclinical test service solutions for various drugs, and have accumulated rich R&D experience in drug metabolism, pharmacokinetics, pharmacodynamics research, and toxicology. With high-quality data and fast turnaround time, Medicilon preclinical research platform could help clients to develop their drugs faster, better and with less cost. As early as 2009, the preclinical research laboratory of Medicilon's wholly-owned subsidiary, Medicilon Preclinical Research (Shanghai) LLC, obtained the certification of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) and reached the GLP standard of both US FDA and China's NMPA, as well as the preclinical safety evaluation with the GLP specification of the Organization for European Economic Cooperation and Development (OECD). Preclinical Services of Medicilon: preclinical research services (https://www.medicilon.com/ pharmacodynamic research (https://www.medicilon.com/ pharmacokinetic research (https://www.medicilon.com/ safety evaluation (https://www.medicilon.com/ End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|